Figures computed from official regulatory filings — .
Analysttarget 3.33 USD (+255%) · consensus 5/5 · 3 buy · 0 hold · 0 sell
Ownershipinsiders 1.29% · institutions 23.79% · short 8.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for COGNITION THERAPEUTICS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
34 buys5 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Khattar Jack A. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Monia Brett P | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RICHSTONE ELLEN Btrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fletcher Aaron G.L.track record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wallace Peggy | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Doyle John Brendan | Other | $11K | SEC |
| Ricciardi Lisatrack record | Buy | $10.1K | conv 55ClusterFirst in 12mo | SEC |
| Caggiano Anthony | Buy | $11.1K | conv 66ClusterFirst in 12mo | SEC |
| Doyle John Brendan | Buy | $11.3K | conv 71ClusterFirst in 12mo | SEC |
| Ricciardi Lisatrack record | Other | $6.6K | SEC |
| Doyle John Brendan | Other | $1.7K | SEC |
| Caggiano Anthony | Other | $5.2K | SEC |
| Ricciardi Lisatrack record | Other | $29.2K | SEC |
| Doyle John Brendan | Other | $27.7K | Unusual size | SEC |
| Caggiano Anthony | Other | $27.7K | SEC |
| Ricciardi Lisatrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Caggiano Anthony | Other | $12.9K | SEC |
| Caggiano Anthony | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ricciardi Lisatrack record | Other | $53.3K | SEC |
| Doyle John Brendan | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Doyle John Brendan | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Caggiano Anthony | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Caggiano Anthony | Other | $30.4K | SEC |
| Doyle John Brendan | Other | $14K | SEC |
| Ricciardi Lisatrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |